Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that a new U.S. patent which covers CAMCEVI^® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as “the Orange Book”.

On August 8, 2023, the United States Patent and Trademark Office (USPTO) issued U.S. patent No. 11,717,555 B2, under the title “Pharmaceutical Compositions Having a Selected Release Duration”, which has extended the patent protection on CAMCEVI^® to January 1, 2039. The formulation patent covers not only CAMCEVI^® but also Foresee’s other LHRH products in development.

The listing of the patent brings the total number of Orange Book-listed patents from three to four.

“We are excited to further strengthen our intellectual property protection for CAMCEVI^® and other developing LHRH products with the newly granted patent,” said Dr. Ben Chien, Foresee’s Chairman and CEO. “Additionally, this serves as another milestone to validate our SIF technologies and to potentially bring in more commercial value through the extended patent life and royalty terms.”